Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10466285 | 0.85 | — | — | |
| SCHEMBL8252569 | 0.75 | CREBBP (0.58) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL15610126 | 0.74 | ITGB1 (0.74) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL4756277 | 0.72 | ITGB3 (0.35) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL28570252 | 0.71 | CREBBP (0.38) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL10521970 | 0.71 | CREBBP (0.38) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL681455 | 0.70 | CRBN (0.42) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| Hydrochloric Acid SCHEMBL10659486 | 0.69 | CREBBP (0.37) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL1061581 | 0.68 | CRBN (0.36) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL124234 | 0.68 | CRBN (0.36) | ITGB1ITGA5ITGB3ITGB2ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | ITGB1 2659/4885ITGA5 1878/4885ITGB3 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.